

Precision Cancer Consortium (PCC)



The PCC is a non-profit organization composed of:

AstraZeneca • Bristol Myers Squibb • Johnson & Johnson • Lilly

Many patients lack access to precision oncology and biomarker-driven care, which can limit outcomes. Barriers are often ecosystem-related and cannot be solved by one stakeholder alone.



The PCC is dedicated to a future where every person with cancer—regardless of who they are or where they live—can benefit from **precision oncology**



Through global collaboration, the PCC aims to make **biomarker-informed, data-driven patient identification and personalized care** standard practice

The PCC is driving real-world impact



Proudly nominated at the Precision Medicine Awards 2025



Educating and connecting healthcare professionals (HCPs) through online webinars, think tanks, and congress activities to share awareness of the benefits of precision diagnostics and best practice implementation.



Sharing tools such as a framework for valuing next-generation sequencing (NGS) and comprehensive genomic profiling (CGP) diagnostics, a genomic testing cost calculator, and Lean Six Sigma lab workflow optimization modules.



Visit the PCC website for more information and to download free tools

Why join the PCC?

1

Shape the future of biomarker testing in a way that you cannot do on your own



2

Demonstrate your commitment to patients and the wider precision medicine community



3

Maximize resource utilization and reach



**PRECISION
CANCER
CONSORTIUM**

PCC ID: 271 - Date of preparation June 2026

The PCC is composed of and funded by:
AstraZeneca, Bristol Myers Squibb, Johnson & Johnson,
and Lilly at the time of writing.

Join our mission
to make precision
oncology the new normal
(scan the QR code for more details)
www.precisioncancerconsortium.com



Access to CGP: Improving patient outcomes through equitable access to testing at initial diagnosis for all patients with cancer

Phase 1: Evaluation



Structural and process-based challenges were identified and ranked across several autonomous communities (ACs) in Spain

Phase 2: Actions



Local: Single AC initiative – Galicia

- **What?** Hands-on support to advance CGP implementation
- **Why?** To evaluate and refine actions to advance CGP in Galicia itself and influence other communities



Global: CGP interactive guide

- **What?** A structured, country/region-agnostic interactive online tool
- **Why?** To enable broader implementation of CGP across countries in a consistent and scalable way

Expanding access and adoption of liquid biopsy (LBx) in routine clinical care for the identification of actionable biomarkers in lung, prostate, colorectal, and breast cancers

Phase 1: Evaluation




General barriers to LBx uptake were identified through market research (publication pending)

Phase 2: Testing



Findings were pressure tested in laboratories and clinics in Southern France



Phase 3: Actions



Ongoing: Implement practical solutions to drive utilization of LBx across this network to:

- Improve awareness and adoption
- Reduce logistic hurdles
- Increase testing volumes

Long term: Evaluate opportunities to use learnings to increase access and adoption of LBx outside this region

Future vision and aspirations for 2026-2027

The **Access to CGP** and **LBx** projects will evolve and expand to create lasting impact for patients globally. Core areas of interest for 2026-2027 include the following:



Digital and computational pathology and artificial intelligence (AI)



Minimal residual disease (MRD) and monitoring in the USA



Policy shaping in Japan



Biomarker testing standardization



**PRECISION
CANCER
CONSORTIUM**

PCC ID: 271 - Date of preparation June 2026

The PCC is composed of and funded by:
AstraZeneca, Bristol Myers Squibb, Johnson & Johnson,
and Lilly at the time of writing.

Join our mission
to make precision
oncology the new normal
(scan the QR code for more details)
www.precisioncancerconsortium.com

